Molecular Neurooncology and Neoangiogenesis of Malignant Gliomas

  • Markus Hutterer
  • Günther Stockhammer


Malignant gliomas are the most common and most aggressive primary brain tumors in adults. Advances in surgery, radiotherapy and chemotherapy only have a minor impact on the natural course of these tumors. Due to the dismal prognosis of malignant glioma patients, there is an urgent need for new innovative treatments based on a better understanding of the molecular mechanisms of gliomagenesis. Many growth factors, growth factor receptors – usually receptor tyrosine kinases – and receptor-associated intracellular signaling pathways are critically involved in glioma growth, invasiveness and tumor neovascularization.

Therefore, this chapter highlights the most important signaling pathways involved in initiation and progression of malignant gliomas. The knowledge of these pathways is the rationale of several concepts of new innovative molecular therapies in modern neurooncology.


Vascular Endothelial Growth Factor Glioma Cell Malignant Glioma Vascular Endothelial Growth Factor Expression PTEN Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Anaplastic astrocytoma


Anaplastic glioma


Anaplastic oligodendroglioma


Antisense oligonucleotide


Clinical response


Complete response




Epidermal growth factor


Epidermal growth factor receptor


Extracellular signal regulated kinase


Fibroblast growth factor


Fibroblast growth factor receptor


Glioblastoma multiforme


Growth factor


Growth factor receptor-bound protein 2


Insulin growth factor


Insulin growth factor receptor


Ligand linked targeted toxins


Neutralizing monoclonal antibody


Mitogen-activated protein kinase


MAPK/ERK kinase


Mammalian target of rapamycin


Progressive disease


Platelet-derived growth factor


Platelet-derived growth factor receptor




Proteinkinase C


Phospholipase C


Partial response


Recurrent anaplastic astrocytoma


GTPase-activating protein of Ras


Ras-guanosine-triphosphate, active Ras


Recurrent glioblastoma multiforme


Recurrent high grade Glioma


Receptor tyrosine kinase


Stable disease


Soluble receptor


Small molecule inhibitor of receptors


Small molecule inhibitor of intracellular signaling molecules


Transforming growth factor


Transforming growth factor receptor


  1. Aaronson SA (1991) Growth factors and cancer. Science 254:1146–1153PubMedGoogle Scholar
  2. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074PubMedGoogle Scholar
  3. Andjelkovic M, Alessi DR, Meier R et al (1997) Role of translocation in the activation and function of protein kinase B. J Biol Chem 272:31515–31524PubMedGoogle Scholar
  4. Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32S–40SPubMedGoogle Scholar
  5. Bajetto A, Barbieri F, Pattarozzi A et al (2007) CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro. Neuro-Oncology 9:3–11PubMedGoogle Scholar
  6. Barker FG 2nd, Simmons ML, Chang SM et al (2001) EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:410–418PubMedGoogle Scholar
  7. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMedGoogle Scholar
  8. Belanich M, Pastor M, Randall T et al (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783–788PubMedGoogle Scholar
  9. Biernat W, Huang H, Yokoo H et al (2004) Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol 14:131–136PubMedGoogle Scholar
  10. Birner P, Piribauer M, Fischer I et al (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143PubMedGoogle Scholar
  11. Blancher C, Moore JW, Robertson N et al (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61:7349–7355PubMedGoogle Scholar
  12. Blobe GC, Schiemann WP and Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358PubMedGoogle Scholar
  13. Boguski MS and McCormick F (1993) Proteins regulating Ras and its relatives. Nature 366:643–654PubMedGoogle Scholar
  14. Bollag G and McCormick F (1991) Regulators and effectors of ras proteins. Annu Rev Cell Biol 7:601–632PubMedGoogle Scholar
  15. Brat DJ and Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84:397–405PubMedGoogle Scholar
  16. Brat DJ, Castellano-Sanchez AA, Hunter SB et al (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64:920–927PubMedGoogle Scholar
  17. Brat DJ, Bellail AC and Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology 7:122–133PubMedGoogle Scholar
  18. Brunet A, Bonni A, Zigmond MJ et al (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857–868PubMedGoogle Scholar
  19. Bullitt E, Zeng D, Gerig G et al (2005) Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol 12:1232–1240PubMedGoogle Scholar
  20. Cantley LC and Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96:4240–4245PubMedGoogle Scholar
  21. Cantley LC, Auger KR, Carpenter C et al (1991) Oncogenes and signal transduction. Cell 64:281–302PubMedGoogle Scholar
  22. Cardone MH, Roy N, Stennicke HR et al (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318–1321PubMedGoogle Scholar
  23. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936PubMedGoogle Scholar
  24. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMedGoogle Scholar
  25. Carmeliet P, Lampugnani MG, Moons L et al (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147–157PubMedGoogle Scholar
  26. Carpenter G and Cohen S (1979) Epidermal growth factor. Annu Rev Biochem 48:193–216PubMedGoogle Scholar
  27. Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  28. Choe G, Park JK, Jouben-Steele L et al (2002) Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 8:2894–2901PubMedGoogle Scholar
  29. Couldwell WT, de Tribolet N, Antel JP et al (1992) Adhesion molecules and malignant gliomas: implications for tumorigenesis. J Neurosurg 76:782–791PubMedGoogle Scholar
  30. Datta SR, Brunet A and Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905–2927PubMedGoogle Scholar
  31. Davis S, Aldrich TH, Jones PF et al (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87:1161–1169PubMedGoogle Scholar
  32. de Caestecker MP, Piek E and Roberts AB (2000) Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92:1388–1402PubMedGoogle Scholar
  33. Deeken JF and Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663–1674PubMedGoogle Scholar
  34. Dennis PB, Fumagalli S and Thomas G (1999) Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev 9:49–54PubMedGoogle Scholar
  35. Di Rocco F, Carroll RS, Zhang J et al (1998) Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42:341–346PubMedGoogle Scholar
  36. Ding H, Roncari L, Shannon P et al (2001a) Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61:3826–3836PubMedGoogle Scholar
  37. Ding H, Roncari L, Wu X et al (2001b) Expression and hypoxic regulation of angiopoietins in human astrocytomas. Neuro-Oncology 3:1–10PubMedGoogle Scholar
  38. Duda DG, Cohen KS, Kozin SV et al (2006) Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 107:2774–2776PubMedGoogle Scholar
  39. Duerr EM, Rollbrocker B, Hayashi Y et al (1998) PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16:2259–2264PubMedGoogle Scholar
  40. Dunn IF, Heese O and Black PM (2000) Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 50:121–137PubMedGoogle Scholar
  41. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380PubMedGoogle Scholar
  42. Ekstrand AJ, Sugawa N, James CD et al (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 89:4309–4313Google Scholar
  43. Ekstrand AJ, Longo N, Hamid ML et al (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313–2320Google Scholar
  44. El-Obeid A, Bongcam-Rudloff E, Sorby M et al (1997) Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. Cancer Res 57:5598–5604PubMedGoogle Scholar
  45. Ermoian RP, Furniss CS, Lamborn KR et al (2002) Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8:1100–1106PubMedGoogle Scholar
  46. Feldkamp MM, Lala P, Lau N et al (1999) Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45:1442–1453PubMedGoogle Scholar
  47. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedGoogle Scholar
  48. Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discovery 3:391–400Google Scholar
  49. Fidler IJ (2001) Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 10:257–269, vii-viiiiPubMedGoogle Scholar
  50. Fischer I, Gagner JP, Law M et al (2005) Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297–310PubMedGoogle Scholar
  51. Folkman J (1995) Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757–1763PubMedGoogle Scholar
  52. Frederick L, Wang XY, Eley G et al (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383–1387PubMedGoogle Scholar
  53. Fredriksson L, Li H and Eriksson U (2004) The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15:197–204PubMedGoogle Scholar
  54. Friedlander M, Brooks PC, Shaffer RW et al (1995) Definition of two angiogenic pathways by distinct alpha v integrins. Science 270:1500–1502PubMedGoogle Scholar
  55. Fujisawa H, Reis RM, Nakamura M et al (2000) Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas. Lab Invest 80:65–72PubMedGoogle Scholar
  56. Fukui S, Nawashiro H, Otani N et al (2003) Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors. Cancer 97:3061–3067PubMedGoogle Scholar
  57. Fukumura D, Xavier R, Sugiura T et al (1998) Tumor induction of VEGF promoter activity in stromal cells. Cell 94:715–725PubMedGoogle Scholar
  58. Fukumura D, Xu L, Chen Y et al (2001) Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61:6020–6024PubMedGoogle Scholar
  59. Furuta M, Weil RJ, Vortmeyer AO et al (2004) Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23:6806–6814PubMedGoogle Scholar
  60. Gagnon ML, Bielenberg DR, Gechtman Z et al (2000) Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci USA 97:2573–2578PubMedGoogle Scholar
  61. Gladson CL (1996) Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors. J Neuropathol Exp Neurol 55:1143–1149PubMedGoogle Scholar
  62. Godard S, Getz G, Delorenzi M et al (2003) Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63:6613–6625PubMedGoogle Scholar
  63. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374–3378PubMedGoogle Scholar
  64. Goth R and Rajewsky MF (1974) Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. Proc Natl Acad Sci USA 71:639–643PubMedGoogle Scholar
  65. Gridley T (2007) Vascular biology: vessel guidance. Nature 445:722–723PubMedGoogle Scholar
  66. Grunewald M, Avraham I, Dor Y et al (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124:175–189PubMedGoogle Scholar
  67. Guha A, Dashner K, Black PM et al (1995) Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer 60:168–173PubMedGoogle Scholar
  68. Guha A, Feldkamp MM, Lau N et al (1997) Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15:2755–2765PubMedGoogle Scholar
  69. Guo P, Hu B, Gu W et al (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162:1083–1093PubMedGoogle Scholar
  70. Hackel PO, Zwick E, Prenzel N et al (1999) Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184–189PubMedGoogle Scholar
  71. Hafizi S and Dahlback B (2006) Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 17(4):295–304PubMedGoogle Scholar
  72. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMedGoogle Scholar
  73. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedGoogle Scholar
  74. Hattori K, Heissig B, Tashiro K et al (2001) Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97:3354–3360PubMedGoogle Scholar
  75. Hatva E, Kaipainen A, Mentula P et al (1995) Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 146:368–378PubMedGoogle Scholar
  76. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedGoogle Scholar
  77. Helmlinger G, Yuan F, Dellian M et al (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3:177–182PubMedGoogle Scholar
  78. Hermansson M, Nister M, Betsholtz C et al (1988) Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc Natl Acad Sci USA 85:7748–7752PubMedGoogle Scholar
  79. Hermanson M, Funa K, Hartman M et al (1992) Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213–3219PubMedGoogle Scholar
  80. Hobbs SK, Monsky WL, Yuan F et al (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612PubMedGoogle Scholar
  81. Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998PubMedGoogle Scholar
  82. Hood JD and Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100PubMedGoogle Scholar
  83. Hu B, Jarzynka MJ, Guo P et al (2006) Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res 66:775–783PubMedGoogle Scholar
  84. Huang HS, Nagane M, Klingbeil CK et al (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272:2927–2935PubMedGoogle Scholar
  85. Hubbard SR and Till JH (2000) Protein tyrosine kinase structure and function. Annu Rev Biochem 69:373–398PubMedGoogle Scholar
  86. Hurtt MR, Moossy J, Donovan-Peluso M et al (1992) Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51:84–90PubMedGoogle Scholar
  87. Hutterer M, Knyazev P, Abate A et al (2008) Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 14:130–138PubMedGoogle Scholar
  88. Ichimura K, Schmidt EE, Miyakawa A et al (1998) Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer 22:9–15PubMedGoogle Scholar
  89. Inoki K, Li Y, Zhu T et al (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648–657PubMedGoogle Scholar
  90. Isoe S, Naganuma H, Nakano S et al (1998) Resistance to growth inhibition by transforming growth factor-beta in malignant glioma cells with functional receptors. J Neurosurg 88:529–534PubMedGoogle Scholar
  91. Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280PubMedGoogle Scholar
  92. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4:655–657PubMedGoogle Scholar
  93. Jain RK, Munn LL and Fukumura D (2002) Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2:266–276PubMedGoogle Scholar
  94. Jain RK, Tong RT and Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67:2729–2735PubMedGoogle Scholar
  95. Janssen JW, Schulz AS, Steenvoorden AC et al (1991) A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 6:2113–2120PubMedGoogle Scholar
  96. Jennings MT and Pietenpol JA (1998) The role of transforming growth factor beta in glioma progression. J Neurooncol 36:123–140PubMedGoogle Scholar
  97. Jiang BH, Jiang G, Zheng JZ et al (2001) Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12:363–369PubMedGoogle Scholar
  98. Johansson M, Brannstrom T, Bergenheim AT et al (2002) Spatial expression of VEGF-A in human glioma. J Neurooncol 59:1–6PubMedGoogle Scholar
  99. Joy A, Moffett J, Neary K et al (1997) Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene 14:171–183PubMedGoogle Scholar
  100. Karcher S, Steiner HH, Ahmadi R et al (2006) Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 118:2182–2189PubMedGoogle Scholar
  101. Kita D, Yonekawa Y, Weller M et al (2007) PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113:295–302PubMedGoogle Scholar
  102. Klagsbrun M (1989) The fibroblast growth factor family: structural and biological properties. Prog Growth Factor Res 1:207–235PubMedGoogle Scholar
  103. Kleihues P and Sobin LH (2000) World Health Organization classification of tumors. Cancer 88:2887PubMedGoogle Scholar
  104. Knobbe CB, Merlo A and Reifenberger G (2002) Pten signaling in gliomas. Neuro-Oncology 4:196–211PubMedGoogle Scholar
  105. Komine C, Watanabe T, Katayama Y et al (2003) Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 13:176–184PubMedGoogle Scholar
  106. Kubiatowski T, Jang T, Lachyankar MB et al (2001) Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 95:480–488PubMedGoogle Scholar
  107. Lal A, Glazer CA, Martinson HM et al (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335–3339PubMedGoogle Scholar
  108. Le Roith D (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336:633–640PubMedGoogle Scholar
  109. Leenders WP, Kusters B and de Waal RM (2002) Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9:83–87PubMedGoogle Scholar
  110. Leon SP, Folkerth RD and Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362–372PubMedGoogle Scholar
  111. Leslie JD, Ariza-McNaughton L, Bermange AL et al (2007) Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134:839–844PubMedGoogle Scholar
  112. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947PubMedGoogle Scholar
  113. Lokker NA, Sullivan CM, Hollenbach SJ et al (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735PubMedGoogle Scholar
  114. Lowy DR and Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62:851–891PubMedGoogle Scholar
  115. Machein MR and Plate KH (2000) VEGF in brain tumors. J Neurooncol 50:109–120PubMedGoogle Scholar
  116. Machein MR, Kullmer J, Fiebich BL et al (1999) Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 44:732–740; discussion 740–731PubMedGoogle Scholar
  117. Maehama T and Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375–13378PubMedGoogle Scholar
  118. Maher EA, Furnari FB, Bachoo RM et al (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311–1333PubMedGoogle Scholar
  119. Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60PubMedGoogle Scholar
  120. Maity A, Pore N, Lee J et al (2000) Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60:5879–5886PubMedGoogle Scholar
  121. Manfioletti G, Brancolini C, Avanzi G et al (1993) The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 13:4976–4985PubMedGoogle Scholar
  122. Margison GP and Kleihues P (1975) Chemical carcinogenesis in the nervous system. Preferential accumulation of O6-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of N-methyl-N-nitrosourea. Biochem J 148:521–525PubMedGoogle Scholar
  123. Martin KA and Blenis J (2002) Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 86:1–39PubMedGoogle Scholar
  124. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67:753–791PubMedGoogle Scholar
  125. Maxwell M, Naber SP, Wolfe HJ et al (1990) Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. J Clin Invest 86:131–140PubMedGoogle Scholar
  126. Melder RJ, Koenig GC, Witwer BP et al (1996) During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2:992–997PubMedGoogle Scholar
  127. Millauer B, Shawver LK, Plate KH et al (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579PubMedGoogle Scholar
  128. Mineo JF, Bordron A, Baroncini M et al (2007) Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85:281–287PubMedGoogle Scholar
  129. Monsky WL, Fukumura D, Gohongi T et al (1999) Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 59:4129–4135PubMedGoogle Scholar
  130. Nakamura M, Yang F, Fujisawa H et al (2000) Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 59:539–543PubMedGoogle Scholar
  131. Nakamura M, Watanabe T, Klangby U et al (2001) p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159–168PubMedGoogle Scholar
  132. Nakamura M, Ishida E, Shimada K et al (2005) Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest 85:165–175PubMedGoogle Scholar
  133. Narita Y, Nagane M, Mishima K et al (2002) Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62:6764–6769PubMedGoogle Scholar
  134. Neuwelt E, Abbott NJ, Abrey L et al (2008) Strategies to advance translational research into brain barriers. Lancet Neurol 7:84–96PubMedGoogle Scholar
  135. Nishikawa R, Ji XD, Harmon RC et al (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727–7731PubMedGoogle Scholar
  136. O'Bryan JP, Frye RA, Cogswell PC et al (1991) axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11:5016–5031PubMedGoogle Scholar
  137. Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899PubMedGoogle Scholar
  138. Ohgaki H and Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479–489PubMedGoogle Scholar
  139. Ohgaki H and Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453PubMedGoogle Scholar
  140. Padera TP, Stoll BR, Tooredman JB et al (2004) Pathology: cancer cells compress intratumour vessels. Nature 427:695PubMedGoogle Scholar
  141. Park JS, Qiao L, Su ZZ et al (2001) Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 20:3266–3280PubMedGoogle Scholar
  142. Plate KH (1999) Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol 58:313–320PubMedGoogle Scholar
  143. Plate KH and Mennel HD (1995) Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 47:89–94PubMedGoogle Scholar
  144. Plate KH, Breier G, Farrell CL et al (1992a) Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67:529–534PubMedGoogle Scholar
  145. Plate KH, Breier G, Weich HA et al (1992b) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848PubMedGoogle Scholar
  146. Plate KH, Breier G, Weich HA et al (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520–529PubMedGoogle Scholar
  147. Platten M, Wick W and Weller M (2001) Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 52:401–410PubMedGoogle Scholar
  148. Qian XC and Brent TP (1997) Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 57:3672–3677PubMedGoogle Scholar
  149. Rameh LE and Cantley LC (1999) The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274:8347–8350PubMedGoogle Scholar
  150. Rasheed BK, McLendon RE, Friedman HS et al (1995) Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10:2243–2246PubMedGoogle Scholar
  151. Rasheed BK, Stenzel TT, McLendon RE et al (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57:4187–4190PubMedGoogle Scholar
  152. Reiss Y, Machein MR and Plate KH (2005) The role of angiopoietins during angiogenesis in gliomas. Brain Pathol 15:311–317PubMedGoogle Scholar
  153. Ridgway J, Zhang G, Wu Y et al (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083–1087PubMedGoogle Scholar
  154. Rowinsky EK, Windle JJ and Von Hoff DD (1999) Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17:3631–3652PubMedGoogle Scholar
  155. Rutka JT, Apodaca G, Stern R et al (1988) The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 69:155–170PubMedGoogle Scholar
  156. Sakata K, Kato S, Fox JC et al (2002) Autocrine signaling through Ras regulates cell survival activity in human glioma cells: potential cross-talk between Ras and the phosphatidylinositol 3-kinase-Akt pathway. J Neuropathol Exp Neurol 61:975–983PubMedGoogle Scholar
  157. Salmaggi A, Eoli M, Frigerio S et al (2003) Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 62:297–303PubMedGoogle Scholar
  158. Samoto K, Ikezaki K, Ono M et al (1995) Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55:1189–1193PubMedGoogle Scholar
  159. Samuels V, Barrett JM, Bockman S et al (1989) Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. Am J Pathol 134:894–902PubMedGoogle Scholar
  160. Sano T, Lin H, Chen X et al (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820–1824PubMedGoogle Scholar
  161. Sasaki H, Zlatescu MC, Betensky RA et al (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159:359–367PubMedGoogle Scholar
  162. Schmelzle T and Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253–262PubMedGoogle Scholar
  163. Sekulic A, Hudson CC, Homme JL et al (2000) A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60:3504–3513PubMedGoogle Scholar
  164. Shapiro JR (2001) Genetics of nervous system tumors. Hematol Oncol Clin North Am 15:961–977PubMedGoogle Scholar
  165. Shawver LK, Slamon D and Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123PubMedGoogle Scholar
  166. Shweiki D, Itin A, Soffer D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845PubMedGoogle Scholar
  167. Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246–1256PubMedGoogle Scholar
  168. Sonoda Y, Ozawa T, Aldape KD et al (2001) Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61:6674–6678PubMedGoogle Scholar
  169. Stan AC, Nemati MN, Pietsch T et al (1995) In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 82:1044–1052PubMedGoogle Scholar
  170. Steck PA, Pershouse MA, Jasser SA et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362PubMedGoogle Scholar
  171. Stefanik DF, Rizkalla LR, Soi A et al (1991) Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 51:5760–5765PubMedGoogle Scholar
  172. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018PubMedGoogle Scholar
  173. Stockhammer G, Obwegeser A, Kostron H et al (2000a) Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol 100:101–105PubMedGoogle Scholar
  174. Stockhammer G, Poewe W, Burgstaller S et al (2000b) Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 54:1670–1676PubMedGoogle Scholar
  175. Stoeckli ET and Landmesser LT (1995) Axonin-1, Nr-CAM, and Ng-CAM play different roles in the in vivo guidance of chick commissural neurons. Neuron 14:1165–1179PubMedGoogle Scholar
  176. Stratmann A, Risau W and Plate KH (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459–1466PubMedGoogle Scholar
  177. Strebhardt K and Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480PubMedGoogle Scholar
  178. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedGoogle Scholar
  179. Sun L, Hui AM, Su Q et al (2006) Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9:287–300PubMedGoogle Scholar
  180. Takahashi JA, Fukumoto M, Igarashi K et al (1992) Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76:792–798PubMedGoogle Scholar
  181. Tamura M, Gu J, Tran H et al (1999) PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 91:1820–1828PubMedGoogle Scholar
  182. Tang P, Steck PA and Yung WK (1997) The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol 35:303–314PubMedGoogle Scholar
  183. Tee AR, Fingar DC, Manning BD et al (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571–13576PubMedGoogle Scholar
  184. Tohma Y, Gratas C, Biernat W et al (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57:684–689PubMedGoogle Scholar
  185. Trojan J, Cloix JF, Ardourel MY et al (2007) Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145:795–811PubMedGoogle Scholar
  186. Tsai JC, Goldman CK and Gillespie GY (1995) Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82:864–873PubMedGoogle Scholar
  187. Tso CL, Freije WA, Day A et al (2006) Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res 66:159–167PubMedGoogle Scholar
  188. Uhm JH, Dooley NP, Villemure JG et al (1997) Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol Sci 24:3–15PubMedGoogle Scholar
  189. Vajkoczy P, Knyazev P, Kunkel A et al (2006) Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103:5799–5804PubMedGoogle Scholar
  190. Valk PE, Mathis CA, Prados MD et al (1992) Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33:2133–2137PubMedGoogle Scholar
  191. Varlet P, Guillamo JS, Nataf F et al (2000) Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26:379–389PubMedGoogle Scholar
  192. Varnum BC, Young C, Elliott G et al (1995) Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 373:623–626PubMedGoogle Scholar
  193. Vazquez F and Sellers WR (2000) The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470:M21–35PubMedGoogle Scholar
  194. Vazquez F, Ramaswamy S, Nakamura N et al (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20:5010–5018PubMedGoogle Scholar
  195. Vazquez F, Grossman SR, Takahashi Y et al (2001) Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276:48627–48630PubMedGoogle Scholar
  196. Vivanco I and Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501PubMedGoogle Scholar
  197. Vogelstein B and Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799PubMedGoogle Scholar
  198. von Deimling A, Louis DN and Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15:328–338Google Scholar
  199. Wang SI, Puc J, Li J et al (1997) Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183–4186PubMedGoogle Scholar
  200. Walker MD, Green SB, Byar DP et al. (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329Google Scholar
  201. Watanabe K, Tachibana O, Sata K et al (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6:217–223; discussion 223–214PubMedGoogle Scholar
  202. Watts GS, Pieper RO, Costello JF et al (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612–5619PubMedGoogle Scholar
  203. Weissman DE (1988) Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. J Clin Oncol 6:543–551PubMedGoogle Scholar
  204. Wen S, Stolarov J, Myers MP et al (2001) PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98:4622–4627PubMedGoogle Scholar
  205. Wesseling P, Ruiter DJ and Burger PC (1997) Angiogenesis in brain tumors; pathobiological and clinical aspects. J Neurooncol 32:253–265PubMedGoogle Scholar
  206. Westermark B, Heldin CH and Nister M (1995) Platelet-derived growth factor in human glioma. Glia 15:257–263PubMedGoogle Scholar
  207. Wick W, Platten M and Weller M (2001) Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta. J Neurooncol 53:177–185PubMedGoogle Scholar
  208. Williams CK, Li JL, Murga M et al (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107:931–939PubMedGoogle Scholar
  209. Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMedGoogle Scholar
  210. Wymann MP and Pirola L (1998) Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1436:127–150PubMedGoogle Scholar
  211. Yamaguchi F, Saya H, Bruner JM et al (1994) Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 91:484–488PubMedGoogle Scholar
  212. Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248PubMedGoogle Scholar
  213. Yu H and Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489PubMedGoogle Scholar
  214. Yuan F, Salehi HA, Boucher Y et al (1994) Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 54:4564–4568PubMedGoogle Scholar
  215. Zagzag D, Hooper A, Friedlander DR et al (1999) In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159:391–400PubMedGoogle Scholar
  216. Zagzag D, Zhong H, Scalzitti JM et al (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606–2618PubMedGoogle Scholar
  217. Zwick E, Bange J and Ullrich A (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8:17–23PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of Neurology (Neurooncology Group)Medical University of InnsbruckInnsbruckAustria

Personalised recommendations